Investment bank De Rothschild is setting up a €250-million fund to invest in life-science companies, the Financial Times reports.
The private-equity fund will invest in European and US biotech, pharmaceutical and medical technology companies, although investors have turned away from this kind of activities in the past years, the newspaper says.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.